Guide

Radiopharmaceutical manufacturing — the global readiness hub

Radiopharmaceuticals are unlike any other regulated product: half-lives measured in minutes to days, conditional release at T0 before sterility is known, dispensing decay-corrected to administration time, and a regulatory stack that crosses drug GMP, nuclear-materials licensing, and pharmacy compounding rules. With roughly 120 commercial-scale producers worldwide and an explosion of theranostic pipelines (Lu-177-PSMA, Lu-177-DOTATATE, Ac-225, F-18, Ga-68), the operational playbook is small, specialized, and under-documented. This hub indexes V5 Ultimate's working guides on the regulations, isotopes, and release models that actually matter on the production floor.

Start free trial Free trial, no credit card, onboard in days, not months.

Why radiopharma is its own regulatory species

Finished radiopharmaceuticals do not slot cleanly into 21 CFR 211 or EudraLex Vol 4 Part I. The US carved out 21 CFR Part 212 specifically for PET drugs in 2009; the rest of the radiopharma estate sits across 21 CFR 211 (residual), USP general chapters <797>/<823>/<825>, and 10 CFR Part 35 (NRC medical use). The EU layers EudraLex Annex 3 (Manufacture of Radiopharmaceuticals) over Annex 1 (sterile). Most products are released conditionally — administered to a patient before sterility test, endotoxin, or final QC is complete — which has no analogue in conventional pharma.

The six operational sub-problems

1) Cyclotron + synthesis-module integration and electronic batch record (EBR) capture in seconds-to-minutes timeframes. 2) Aseptic dispense in a shielded hot cell with Annex 1 contamination control strategy and decay-corrected dose at T0. 3) Conditional / parametric release with documented post-release sterility and endotoxin follow-up. 4) Generator elution control (Ga-68, Tc-99m) with breakthrough testing. 5) Therapeutic isotope handling (Lu-177, Ac-225, I-131) under combined NRC/EU GMP control. 6) Patient-specific dose dispensing logs and traceability to the administering site.

Reading order

Start with the regulation guide that matches your product (21 CFR 212 for PET, USP <825> for compounding pharmacies, 10 CFR 35 for therapeutic medical-use licensees). Then read the isotope-specific guides (Lu-177-PSMA and Ga-68 generator) for the unit-operation detail. Finish with the batch-release guide — it is the highest-risk and least-documented part of the operating model.

How V5 Ultimate fits

V5 runs the electronic batch record, environmental monitoring, deviation, OOS, training, supplier qualification, and release workflow under one PQS configured for radiopharmaceutical timing. The radiopharma industry playbook on V5 Ultimate walks through cyclotron-to-dispense as a single integrated flow and is linked from every guide below.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

21 CFR Part 11

Part 11 makes electronic records and signatures legally defensible by requiring validation, audit trails, security, signature controls, accurate copies, and retention in line with underlying FDA recordkeeping rules.

CAPA

CAPA is a structured, evidence-based cycle to fix problems, prevent recurrence, and confirm results meet regulatory expectations.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Industries this hits hardest

Frequently asked

How many radiopharmaceutical manufacturers exist globally?

Around 120 commercial-scale producers, concentrated in the US (Cardinal Health Nuclear Pharmacy Services, Jubilant Radiopharma, PharmaLogic, GE HealthCare), Europe (Curium, Eckert & Ziegler, ITM, Novartis AAA), Japan (Nihon Medi-Physics), and a growing cohort of theranostic CDMOs. Hospital-based radiopharmacies and academic cyclotron centers add several hundred more, but most operate under USP <825> compounding rather than 21 CFR 212 commercial manufacture.

Is 21 CFR 212 a complete cGMP framework on its own?

For PET drugs, yes — 212 was written so PET producers do not have to comply with 211 in full. For non-PET radiopharmaceuticals (therapeutics, generators, SPECT tracers), 211 still applies with radiopharma-specific accommodations from FDA guidance.

What is conditional release and is it legal?

Yes — it is the only practical model for short-lived isotopes. The product is released and administered before all QC (sterility, endotoxin, sometimes radiochemical purity) is final, on the basis of validated parametric controls. The full sterility and endotoxin results are required post-administration; any failure triggers patient-notification protocols. It is recognised in 21 CFR 212.70(f), USP <823>, EU Annex 3, and PIC/S PE 010.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →